Castleman disease and TAFRO syndrome.

Abstract

Although Castleman disease was first described in 1956, this disease includes various conditions, including unicentric Castleman disease with hyaline vascular histology, human herpesvirus-8 (HHV-8) related multicentric Castleman disease, idiopathic multicentric Castleman disease, and mimics of Castleman disease associated with other conditions. To date, Castleman disease remains incompletely understood due to its rareness and difficulties in clinical and pathological diagnosis. TAFRO syndrome was reported in Japan in 2010. Because lymph node histology is similar in patients with TAFRO syndrome and Castleman disease, TAFRO syndrome is described as a related disorder of Castleman disease. Clinically, however, these conditions differ markedly. Although elevated interleukin-6 (IL-6) expression is characteristic of Castleman disease, increased expression of IL-6 may occur in patients with other diseases, making elevated IL-6 unsuitable for differential diagnosis. Further understanding of these disorders requires the identification of novel disease-specific biomarkers. This review article therefore outlines the characteristics of Castleman disease and TAFRO syndrome.

• Authors: Yasufumi Masaki, Kotaro Arita, Tomoyuki Sakai, Kazue Takai, Sadao Aoki, Hiroshi Kawabata
• Journal: Annals of hematology (Ann Hematol) Vol. 101 Issue 3 Pg. 485-490 (Mar 2022) ISSN: 1432-0584 [Electronic] Germany
• PMID: 35044513 (Publication Type: Journal Article, Review)
• Copyright: © 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Chemical References

• Interleukin-6

Topics

• Animals
• Castleman Disease (blood, diagnosis, pathology)
• Cytokine Release Syndrome (blood, diagnosis, pathology)
• Diagnosis, Differential
• Humans
• Interleukin-6 (analysis, blood)
• Lymph Nodes (pathology)